- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05639933
Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors (CLEER)
A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
The goal of this clinical trial is to learn about HT-001 Topical Gel for treatment of EGFR inhibitor-induced skin toxicities. The main questions it aims to answer are:
- Determine the therapeutic effect of HT-001 for treatment of patients who develop acneiform rash undergoing Epidermal Growth Factor inhibitor (EGFRI) therapy using the acneiform rash investigator's global assessment scale [ARIGA]
- Evaluate the safety of HT-001 during treatment
Participants will apply HT-001 Gel once per day for 6 weeks, during which the effect on treating acneiform rash or other skin disorders induced by EGFRI therapy will be evaluated using different assessment tools to measure severity of rash, pain, and itching (pruritus), as well as the change in quality of life.
The study will be completed in 2 periods: the first period is open-label (unblinded) and all patients will receive HT-001 topical gel with the active ingredient; the second period is blinded and patients will be randomized to receive one of three concentrations of HT-001 or placebo.
Researchers will compare HT-001 to the placebo in the second period to see if HT-001 provides a significant treatment effect.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a randomized, double-blind, placebo-controlled, multi-center Phase 2a dose-ranging study to evaluate the efficacy, safety, and tolerability of HT-001 for treatment of EGFRI-induced skin toxicity. The study will include adult patients (≥ 18 years of age) scheduled to receive initial or repeat EGFRI therapy.
The study will be conducted in 2 periods: Part 1, an open-label cohort consisting of 12 patients to measure pharmacokinetics of HT 001 gel followed by Part 2, a randomized, parallel arm study comparing 3 dose strengths of HT-001 gel to placebo (HT 001 vehicle). Patients in the randomized cohorts will be randomly assigned to 1 of the 4 treatment arms in a 2:2:2:1 ratio (active groups = 2: placebo = 1).
All patients in both open-label and blinded cohorts will apply the study drug once a day to each area affected with cutaneous toxicity up to 30% body surface area (BSA) involvement, inclusive of skin, scalp, and nails.
The goal of the study is to determine the minimum efficacious dose strength(s) for further investigation. The dose effect, together with the application site safety assessments, and therapeutic effects based on the primary and secondary endpoints will be evaluated.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Hayley Springer
- Phone Number: 646-756-2997
- Email: hayley@hoththerapeutics.com
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- Not yet recruiting
- The George Washington University Medical Faculty Associates
-
Principal Investigator:
- Adam Friedman, MD
-
Contact:
- Study Coordinator
- Phone Number: 202-741-2600
-
-
Florida
-
Miami, Florida, United States, 33125
- Recruiting
- University of Miami
-
Contact:
- Aliette Espinosa
- Phone Number: 305-689-3376
-
Principal Investigator:
- Robert Kirsner, MD
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University in St Louis School of Medicine
-
Contact:
- Mary Tabacchi
-
Contact:
- Stephanie Farris
-
Principal Investigator:
- Milan Anandkat, MD
-
-
New York
-
Bronx, New York, United States, 10467
- Not yet recruiting
- Montefiore Medical Center
-
Contact:
- Study Coordinator
- Phone Number: 718-920-8352
-
Principal Investigator:
- Beth McLellan, MD
-
New Hyde Park, New York, United States, 11042
- Not yet recruiting
- Northwell Physician Partners Dermatology
-
Contact:
- Study Coordinator
-
Principal Investigator:
- Allireza Alloo, MD
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Principal Investigator:
- Anisha Patel, MD
-
Contact:
- Stacie Stutt
- Phone Number: 713-794-1918
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult patient (ie, ≥ 18 years of age at Screening/Baseline [V1]) prescribed an approved EGFRI to treat cancer (indication within the approved labeling for the EGFRI).
Patient has developed a rash or symptoms of a rash (papular and/or pustular eruptions) or symptoms of a rash (cutaneous burning), as assessed by both Common Terminology Criteria for Adverse Events (CTCAE) grading and ARIGA scales (severity
≤ 3) with overall involvement ≤ 30% BSA.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Predicted life expectancy ≥ 3 months.
- Patient is able and willing to comply with contraceptive requirements.
- Patient must have the ability and willingness to attend the necessary visits (telehealth and in person).
- Patient must be willing and able to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.
Exclusion Criteria:
- Patient has severe cutaneous toxicity (severity = 4 on the CTCAE grading and ARIGA scales) or cutaneous toxicity involvement that is > 30% BSA, or other severe systemic toxicity (severity > 3 on the CTCAE v5.0 scale) as a result of EGFRI therapy.
- Patient has any underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely that the patient would comply with the protocol or complete the study per protocol.
- Patient has a history of other skin disorders (eg, atopic dermatitis, psoriasis, recurrent skin infections), or history of illness that, in the opinion of the Investigator, would confound results of the study or pose unwarranted risk in administering study drug to the patient.
Patient has abnormal laboratory values at Screening/Baseline (V1):
- Absolute neutrophil count < 1000/mm3 and WBC count < 3000/mm3
- Platelet count < 50,000/mm3
- Aspartate transaminase (AST) > 2.5 × upper limit of normal (ULN)
- Alanine transaminase (ALT) > 2.5 × ULN
- Bilirubin > 1.5 × ULN
- Creatinine > 1.5 × ULN
- Patient has a prescribed cancer treatment plan that requires radiation treatment to the head, neck, or upper trunk concurrent with EGFRI therapy or has previously received radiation therapy within 4 weeks prior to Screening/Baseline (V1).
- Patient has received aprepitant or other neurokinin-1 receptor antagonist within 4 weeks prior to Screening/Baseline (V1).
- Patient has had prior treatment with an investigational drug within 4 weeks prior to Screening/Baseline (V1), or at least 8 half-lives of the drug, whichever is longer.
- Patient has an active infection (eg, pneumonia) or any uncontrolled disease except for the malignancy that, in the opinion of the Investigator, might confound the result or the study or pose unwarranted risk in administering the study drug to the patient.
- Patient has received non-stable escalating doses of topical antibiotics, topical steroids, or other topical treatments within 14 days prior to Screening/Baseline (V1). Patients who have been on stable doses of topical antibiotics, topical steroids, or other topical treatments for 14 days or more are allowed to be enrolled and to stay on their current prescription. Reduction in dose due to improvement in EGFRI-related toxicities is allowed.
- Patient has used non-stable escalating doses of systemic steroids within 14 days prior to Screening/Baseline (V1) excluding low-dose systemic corticosteroids as part of standard of care for prevention or treatment of chemotherapy-induced nausea and vomiting; acceptability of the steroid and dose is to be determined by the study Investigator. Patients who have been on a stable dose of systemic steroids for 14 days or more are allowed to be enrolled and to stay on their current prescription. Reduction in dose due to improvement in EGFRI-related toxicities is allowed. Use of steroid inhalers and nasal corticosteroids is allowed.
- Patient has received non-stable escalating dose treatment with a systemic antibiotic within 14 days prior to Screening/Baseline (V1). Patients who have been on stable doses of systemic antibiotics for 14 days or more are allowed to be enrolled and to stay on their current prescription. Reduction in dose due to improvement in EGFRI-related toxicities is allowed.
- Patient has received concomitant treatment with pimozide, moderate to strong cytochrome p450 (CYP) 3A4 inhibitors (diltiazem, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir), or strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) within 30 days of Screening/Baseline (V1).
- Patient has a history of hypersensitivity to aprepitant or any component of HT-001.
- Patient is pregnant or lactating at Screening/Baseline (V1) or planning to become pregnant (self or partner) at any time during the study, including the follow-up period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Open-Label PK Cohort
Topical treatment with HT-001 2% Gel unblinded.
|
Topical gel, 2% active
|
Placebo Comparator: Randomized, Double Blind Cohort
Topical treatment with HT-001 (2%, 1%, or 0.5%) or placebo (HT-001 vehicle), blinded
|
Topical gel, 2% active
Topical gel, 1% active
Topical gel, 0.5% active
Topical gel, vehicle gel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acneiform Rash Investigator's Global Assessment Scale [ARIGA ]
Time Frame: 6 weeks
|
Proportion of patients with a grade ≤ 1 based on the Acneiform Rash Investigator's Global Assessment [ARIGA] Scale; novel 5-point scale 0-4 with score of 0 is clear and grade 4 being most severe
|
6 weeks
|
Pharmacokinetics of HT-001 applied topically [Cohort 1] - Area Under the Curve (AUC)
Time Frame: Day 1 and Day 42
|
Characterize pharmacokinetics of HT-001 parameters including: measured drug concentrations above the lower limit of quantitation, number of patients with measurable systemic exposure; if data allow - area under the curve (AUC)
|
Day 1 and Day 42
|
Pharmacokinetics of HT-001 applied topically [Cohort 1] - Peak Plasma Concentration (Cmax)
Time Frame: Day 1 and Day 42
|
Characterize pharmacokinetics of HT-001 parameters including: maximum (or peak) serum concentration (Cmax)
|
Day 1 and Day 42
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pruritus Numeric Rating Scale (NRS)
Time Frame: 3 weeks and 6 weeks
|
Change from Baseline in Pruritus Numeric Rating Scale (average itch and worst itch); The numerical scale is ranked from 0 ("no itch") to 10 ("worst imaginable itch").
|
3 weeks and 6 weeks
|
Pain Numeric Rating Scale
Time Frame: 3 weeks and 6 weeks
|
Change from Baseline in pain based on a 11-point NRS (where "0" indicates "no pain", "5" indicates "moderate pain" and "10" indicates "worst pain imaginable")
|
3 weeks and 6 weeks
|
Change in acneiform rash severity
Time Frame: 3 weeks and 6 weeks
|
Change from Baseline in acneiform rash grade based on the Acneiform Rash Investigator's Global Assessment Scale [ARIGA]; novel 5-point scale 0-4 with score of 0 is clear and grade 4 being most severe
|
3 weeks and 6 weeks
|
Time to improvement
Time Frame: 6 weeks Day 1- Day 42
|
Time to improvement in at least one grade using the Acneiform Rash Investigator's Global Assessment Scale [ARIGA ] for acneiform rash; novel 5-point scale 0-4 with score of 0 is clear and grade 4 being most severe
|
6 weeks Day 1- Day 42
|
Time to rescue therapy
Time Frame: Treatment Day 1- Day 42
|
Time to topical rescue therapy treatment after initiation of HT-001
|
Treatment Day 1- Day 42
|
EGFR Inhibitor dose reduction or discontinuation
Time Frame: Treatment Day 1- Day 42
|
Proportion of patients with EGFRI dose reduction or discontinuation during the 6-week treatment period
|
Treatment Day 1- Day 42
|
Safety and tolerability of HT-001
Time Frame: screening, Day 1 - 42, follow-up (Day 56)
|
Incidence of treatment-emergent adverse events and treatment-emergent serious adverse events
|
screening, Day 1 - 42, follow-up (Day 56)
|
Modified Draize Scale
Time Frame: Day 1, 7, 21, 35, 42, 56
|
Assessment of skin irritation through measurement of cutaneous signs of erythema (score 0-3; 3 is most severe) and edema (add 0.5 if present)
|
Day 1, 7, 21, 35, 42, 56
|
Physical Examination
Time Frame: Day 1, 7, 21, 35, 42, 56
|
full physical examination will include examination of general appearance, skin, neck (including thyroid), eyes, ears, nose, throat, heart, lungs, abdomen, lymph nodes, extremities, and nervous system.
An AE form must be completed for all changes identified as clinically noteworthy.
|
Day 1, 7, 21, 35, 42, 56
|
Height
Time Frame: Screening
|
Height recorded in inches
|
Screening
|
Body weight
Time Frame: Day 1, 21, 42, 56
|
Body weight in pounds.
|
Day 1, 21, 42, 56
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Scoring system for paronychia related to oncologic treatments (SPOT)
Time Frame: Day 1, 7, 21, 35, 42
|
Proportion of patients with improvement in paronychia based on the SPOT scale.
Each parameter of paronychia, such as redness (R), edema (E), discharge (D) and granulation tissue (G), is evaluated on a 4-point scale from 0 to 3. The highest score for each R-E-D-G parameter among all involved fingers (or toes) of the respective hand (or foot) represents the overall score for that parameter on that hand (or foot) - note, the highest scores for the different parameters could originate from different fingers (or toes).
|
Day 1, 7, 21, 35, 42
|
Xerosis Severity Scale
Time Frame: Day 1, 7, 21, 35, 42
|
Proportion of patients with improvement in xerosis using the Xerosis Severity Scale adapted from Guenther et al. (Guenther et al., 2012).
The assessment uses signs and symptoms of xerosis (such as rough/scaling skin, itching, pain, erythema, and fissures) as a composite score to determine the severity classification.
In this scale, "-" indicates not present; "+"indicates a mild symptom; "++" indicates a moderate symptom; and "+++" indicates a severe symptom
|
Day 1, 7, 21, 35, 42
|
Change in Quality of Life (QoL)
Time Frame: Day 1, 21, 42
|
Change in quality of life based on FACT-EGFR-18.
This 18-item QoL assessment was developed by Wagner et al. using a 5-point Likert scale (ie, 0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, and 4 = very much) with a recall period of the past 7 days
|
Day 1, 21, 42
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Mario Lacouture, MD, NYU Grossman Long Island School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLEER-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acneiform Eruption Due to Chemical
-
Northwestern UniversityTerminatedA Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular EruptionAcneiform Rash | Papulopustular EruptionUnited States
-
University Hospital, Strasbourg, FranceRecruitingExposure to Chemical Pollution, OccupationalFrance
-
Lady Davis InstituteRecruitingAcneiform Eruptions | Cancer, Treatment-RelatedCanada
-
Prehospital Center, Region ZealandNot yet recruitingDrowning | Drowning, Near | Submersion | Submersion - Accidental | Submersion or Drowning Due to Being Washed Overboard | Submersion or Drowning Due to Being Thrown Overboard | Submersion or Drowning Due to Ship Sinking, Water Skier Injured | Submersion or Drowning Due to Boat Submerging, Swimmer... and other conditionsDenmark
-
Qazvin University Of Medical SciencesCompletedPain Due to Propofol Injection | Hemodynamic Changes Due to Propofol InjectionIran, Islamic Republic of
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedPoor Metabolizer Due to Cytochrome P450 CYP2C9 Variant | Poor Metabolizer Due to Cytochrome p450 CYP2C19 VariantBrazil
-
The University of The West IndiesCompletedPlatelet Dysfunction Due to DrugsTrinidad and Tobago
-
University of UtahNational Aeronautics and Space Administration (NASA)CompletedRespiratory Complications Due to Anesthesia
-
The University of The West IndiesRecruiting
-
Cardiff UniversityCompletedPlatelet Dysfunction Due to AspirinUnited Kingdom
Clinical Trials on HT-001 2% Topical Gel
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Sol-Gel Technologies, Ltd.TerminatedBasal Cell Nevus SyndromeUnited States, France, Belgium, Denmark, Germany, Italy, Netherlands, Spain, United Kingdom
-
BioPharmX, Inc.Completed
-
Rhodes Pharmaceuticals, L.P.ORA, Inc.Completed
-
Glia, LLCCompletedContact Lens Discomfort | Contact Lens-induced Corneal Disorder | Contact Lens Acute Red Eye | Contact Lens-induced Corneal Fluorescein StainingUnited States
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Maruho Co., Ltd.CompletedUsual Type Vulval Intraepithelial Neoplasia (uVIN)Netherlands
-
Maruho Co., Ltd.Completed
-
Maruho Co., Ltd.CompletedAcne VulgarisUnited States
-
BioPharmX, Inc.CompletedModerate to Severe Papulopustular RosaceaUnited States